Role of previous hospitalization in clinically-significant MRSA infection among HIV-infected inpatients: results of a case-control study by Drapeau, Cecilia MJ et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Infectious Diseases
Open Access Research article
Role of previous hospitalization in clinically-significant MRSA 
infection among HIV-infected inpatients: results of a case-control 
study
Cecilia MJ Drapeau1, Claudio Angeletti2, Anna Festa3 and Nicola Petrosillo*1
Address: 12nd Infectious Diseases Division, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy, 2Epidemiology Department, 
National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy and 3Microbiology Laboratory, National Institute for Infectious Diseases 
"L. Spallanzani", Rome, Italy
Email: Cecilia MJ Drapeau - c.drapeau@yahoo.it; Claudio Angeletti - angeletti@inmi.it; Anna Festa - festa@inmi.it; 
Nicola Petrosillo* - petrosillo@inmi.it
* Corresponding author    
Abstract
Background: HIV-infected subjects have high incidence rates of Staphylococcus aureus infections,
with both methicillin-susceptible and methicillin-resistant (MRSA) strains. Possible explanations
could include the high burden of colonization, the behavioral risk factors, and the frequent
exposures to health care facilities of HIV-infected patients. The purpose of the study was to assess
the risk factors for clinically- significant methicillin-resistant Staphylococcus aureus (CS-MRSA)
infections in HIV-infected patients admitted to Infectious Diseases Units.
Methods: From January 1, 2002 to December 31, 2005, we conducted a retrospective case-
control (1:2) study. We identified all the cases of CS-MRSA infections in HIV-infected patients
admitted to the National Institute for Infectious Diseases (INMI) "Lazzaro Spallanzani" in the 4-year
study period. A conditional logistic regression model was used to identify risk factors for CS-MRSA
infection.
Results: We found 27 CS-MRSA infections, i.e. 0.9 CS-MRSA infections per 100 HIV-infected
individuals cared for in our Institute. At multivariate analysis, independent predictors of CS-MRSA
infection were cumulative hospital stay, invasive procedures in the previous year, and low CD4 cell
count. Particularly, the risk for CS-MRSA increased by 14% per an increase of 5 days hospitalization
in the previous year. Finally, we identified a low frequency of community-acquired MRSA infections
(only 1 of 27; 3.7%) among HIV-infected patients.
Conclusion:  Clinicians should be aware of the risk for CS-MRSA infection in the clinical
management of HIV-infected patients, especially in those patients with a low CD4 cell count, longer
previous hospital stay, and previous invasive procedures.
Background
According to the European Antimicrobial Resistance Sur-
veillance System 2004 report, the overall prevalence of
methicillin-resistant S. aureus  (MRSA) isolates in Euro-
pean hospitals is around 24% [1], and Italy is considered
to be one of the highest incidence countries (about 50%)
Published: 30 April 2007
BMC Infectious Diseases 2007, 7:36 doi:10.1186/1471-2334-7-36
Received: 23 September 2006
Accepted: 30 April 2007
This article is available from: http://www.biomedcentral.com/1471-2334/7/36
© 2007 Drapeau et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2007, 7:36 http://www.biomedcentral.com/1471-2334/7/36
Page 2 of 6
(page number not for citation purposes)
[1]. MRSA infections represent a substantial burden in
terms of morbidity, mortality, and costs [2]. Established
risk factors for health care-associated MRSA (HC-MRSA)
infections include recent hospitalization or surgery, resi-
dence in a long-term care facility, dialysis, indwelling per-
cutaneous devices and catheters [3,4]. Moreover, in the
last decades, several cases of MRSA infections without
established risk factors for health care-associated acquisi-
tion have been documented and referred to as commu-
nity-associated MRSA (CA-MRSA) infections [5].
HIV-infected subjects have high incidence rates of S.
aureus infections [6-10] probably due to the high burden
of colonization [8,11-14], to behavioral risk factors [15]
and to frequent health care facility exposures [9,16].
We have retrospectively reviewed the cases of CS-MRSA
infections occurring among HIV-infected patients admit-
ted to our Infectious Diseases hospital, with the aim to
evaluate the clinical and epidemiological associated risk
factors.
Methods
We conducted a retrospective case-control study on HIV-
infected patients admitted to our Institute for Infectious
Diseases "L. Spallanzani, Rome from January 1, 2002 to
December 31, 2005. Approximately 3,000 HIV-infected
patients were followed up in our outpatient facility in the
4-year study period. We collected all the microbiological
reports yielding MRSA isolates from different body sites
except stool with their respective antibiotic sensitivity tests
reported at the computer database of our Institute's
microbiological laboratory. Microbiological cultures were
taken before empirical antibiotic treatment. Surveillance
cultures for colonization were excluded from the study.
Sensitivity testing at our laboratory was performed using
Phoenix (Becton Dickinson) automated system. MRSA
was defined as minimum inhibiting concentration ≥ 4
micrograms/milliliter for oxacillin.
Medical records were reviewed to identify those patients
who had a documented clinically-significant MRSA (CS-
MRSA) infection at isolation time. The clinical signifi-
cance of each MRSA isolate was settled on one or more of
the following criteria: 1) a positive MRSA culture from a
normally sterile body site; 2) documented clinical diagno-
sis of infection at isolation time (e.g. sputum isolates in
patients with documented pneumonia). Moreover, infor-
mation about the patient's demographic and clinical fea-
tures (sex, age, HIV risk factor) was ascertained. The MRSA
isolates were classified according to the source of isola-
tion, as follows: 1) skin, soft tissue isolates; 2) respiratory
isolates including sputum, bronchoalveolar lavage fluid
and pleural fluid; 3) blood isolates.
Further investigation was conducted through the hospital
computer database and the past medical records review,
to assess the following data concerning the patient's
immunological, clinical and hospitalization history prior
to CS-MRSA infection onset: 1) median CD4 cell count
during past half year; 2) median log10 HIV plasma viral
load during past half year; 3) HIV clinical group according
to Centers for Disease Control and Prevention (CDC),
Atlanta; 4) any antiretroviral (ARV) therapy during past
half year; 5) any cotrimoxazole prophylaxis in the previ-
ous 3 months; 6) peritoneal or haemodialysis or 7) sur-
gery within 12 months before the MRSA infection; 8)
presence of a percutaneous device or indwelling vascular
catheter at the time of infection or placed in the past 12
months; 9) total number of hospital days and 10) total
number of clinical visits to our outpatient facility in the
previous year. Time period for ARV therapy and cotrimox-
azole prophylaxis was arbitrarily selected according to
previous studies [15].
CS-MRSA infection was defined either health care or com-
munity-associated, based on established criteria for defi-
nition of "community-associated MRSA infection" [17].
In particular, infection was considered as health care-asso-
ciated if the patient had a clinical history of the following
risk factors: MRSA infection identified after 48 hours of
admission to hospital; a history of hospitalization, sur-
gery, dialysis or residence in long-term care facility within
one year of the MRSA culture date; a permanent indwell-
ing catheter or percutaneous medical device present at the
time of culture or a known positive culture for MRSA prior
to the study period. Lack of the above health care risk fac-
tors led to community-associated MRSA infection case
definition.
A retrospective case control-study was performed, consid-
ering as cases those HIV-infected patients with MRSA
infection identified during the hospital stay, and as con-
trols those HIV-infected patients without MRSA infection,
admitted to the same wards in the study period. Controls
were randomized 1:2 and matched by sex and age.
To assess potential risk factors for CS-MRSA infection, we
used a conditional logistic regression model and results
were exposed in terms of Odds Ratio (OR) with their
respective 95% Confidence Interval (CI). We performed a
univariate analysis by adjusting each variable for age at
enrolment (< = 42 years and >42 years of age), in order to
avoid any residual confounding due to the matching of
the variables. All the covariates that were found to be sig-
nificantly associated (p < 0.05) with CS-MRSA infection
were included in a multivariate model, and afterwards,
using a stepwise backward procedure, we selected the final
model that included the following variables: age at the
enrollment, total number of hospital days in the previousBMC Infectious Diseases 2007, 7:36 http://www.biomedcentral.com/1471-2334/7/36
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year (modeled as continuous variable), number of outpa-
tient visits in the 12 months prior to MRSA diagnosis (0–
1 visit and more than 1 visit), any submission to invasive
procedures (including percutaneous device or indwelling
vascular catheter present at the time of infection or placed
in the past 12 months, any peritoneal or haemodialysis,
and surgical procedures within the past year), and the
median CD4 cell count in the previous six months. We
also plotted the trend of OR according to total number of
hospital days in the previous year, by dividing the patients
with at least one day of hospitalization in three groups of
approximately the same number of days (0, 1–12, 14–45
and >45 days), and performed a test to verify its signifi-
cance.
Since the data reported in our study was collected by
patient's chart review, and no additional information or
any other intervention was made for the purpose of the
study, no specific ethical approval was requested accord-
ing to the regulations of our institute.
Results
During the 4-year study period, 5,257 admissions of HIV-
infected patients occurred at our Institute for Infectious
Diseases "Lazzaro Spallanzani", Rome, Italy. The micro-
biological computer database found out a total of 28 HIV-
infected patients yielding positive MRSA cultures; 27
patients had CS-MRSA infection, and accounted for 0.5%
of total admissions of HIV-infected patients, and for 0.9%
of total HIV-infected patients. Males were 20 (74%);
median age was 43 years (range 38–48). Twenty out of
them (74%) had median CD4 < 200/microliter (μl), and
9 (34.6%) had median log10 HIV plasma viral load ≤ 2.99
copies/milliliter (cp/ml). Four (14.8%) and 23 (85.2%)
patients were classified as HIV group B, and C, respec-
tively. Fifty-four controls were enrolled; males were 40
(74%), median age was 44 years (range 37–48). Thirty-
two patients (59.2%) had CD4 ≥ 200/μl, 14 patients
(26%) had median log10 HIV plasma viral load ≤ 2.99 cp/
ml. Four (7.4%), 22 (40.7%), and 28 (51.8%) patients
were respectively classified as CDC group A, B, and C. No
significant differences were found according to HIV risk
factors; particularly drug users were 55.6% among cases
and 57.3% among controls.
Of the 27 HIV-infected patients, primary sources of MRSA
were distributed as follows: 11 (40.8%) blood, 8 (29.6%)
skin and soft tissue, and 8 (29.6%) respiratory (1 pleural
fluid, 2 bronchoalveolar fluid lavage, 5 sputum).
Among the 27 patients with MRSA infection, 17 (63%)
had a MRSA infection identified within 48 hours of
admission (7 had pneumonia, 6 had skin or soft tissue
infections, 4 had sepsis); 10 (37%) patients evidenced
MRSA infection during the hospital stay (8 had sepsis of
which 2 were indwelling vascular device-related, 2 had
skin and soft tissue infections). According to the above
mentioned criteria, twenty-six out of 27 patients had
health care-associated, and only 1 had community-associ-
ated MRSA infection. Neither cases nor controls were
involved in any case clustering or outbreak during the
study period.
Univariate analysis revealed that the following variables
were associated with the occurrence of CS-MRSA infec-
tion: longer cumulative hospital stay in the previous year,
less than 2 outpatient visit in the previous year, invasive
procedures in the previous year, and CD4 cell count <
200/μl. Moreover, the administration of cotrimoxazole
prophylaxis in the previous 4 months was more common
among cases (29.6%) than controls (9.3%), and close to
significancy (p = 0.051). At multivariate analysis, cumula-
tive hospital stay, invasive procedures in the previous
year, and CD4 cell count in the previous 6 months
remained associated with CS-MRSA infection (Table 1).
Of note, the risk for CS-MRSA increased by 14% per an
increase of 5 days hospitalization. The odds ratios of CS-
MRSA infection according to cumulative hospital stay in
the previous year (p-value for trend = 0.04) are reported in
Figure 1. Mortality rate was 6/27 (22%) among cases and
6/54 (11%) among controls (OR 2.28; 95% CI = 0.66–
7.91; p = 0.10).
Discussion
In our 4-year study, we found a 0.5 rate of CS-MRSA infec-
tions per 100 admissions of HIV-infected patients, and an
average 0.9 CS-MRSA infections per 100 HIV-infected
patients followed up in our outpatient facility. The MRSA
infection rate we found among HIV-infected patients is
slightly lower than those reported in the literature (range
1.9%–3%) [15,16]. Possible explanations could include
the features of the study population (i.e. jail inmates),
[16] and the differences in MRSA clinically-significant
infection definition [16].
In our study we identified a low frequency of CA-MRSA
infection among HIV-infected patients. Indeed, only 1 out
of 27 MRSA patients (3.7%) fulfilled CA-MRSA definition
[17]. This patient was an intravenous drug user who was
admitted to hospital with a diagnosis of cellulitis of the
inferior limb; he had a median CD4 cell count lower than
200/μl, and a median log10 HIV plasma viral load > 2.99
cp/ml. Our findings are in contrast with those of Mat-
thews et al. [15] that reported a 60% of community-asso-
ciated CS-MRSA infections among HIV-infected patients.
However, in a recent study conducted by Seybold et al
[18], 9 out of 116 MRSA bloodstream infections (8%), of
which 22% occurring in HIV-infected patients, were com-
munity-associated. In another study conducted by Naimi
et al. [19], among non HIV-infected patients, 131 out ofBMC Infectious Diseases 2007, 7:36 http://www.biomedcentral.com/1471-2334/7/36
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1,100 MRSA infections (12%) were community-associ-
ated.
To our knowledge, to date in the literature, only few cases
of CA-MRSA infections have been described in Italy
[20,21] and in only one case, i.e. in a non HIV-infected
patient, there was evidence of Panton-Valentine leukoci-
din production [20].
In our retrospective study we found that length of cumu-
lative hospital stay, submission to invasive procedures in
the 12 months prior to MRSA infection onset, and low
CD4 cell count were variables independently associated
with CS-MRSA infection. These findings are in agreement
with previous reports of the literature [9,15,16,22]. More-
over, only in another study [16], the authors found that
total hospital days in the preceding six months were inde-
pendently associated with an increased risk for MRSA col-
onization and infection in HIV-infected patients. The
finding that MRSA infection is related to previous hospi-
talization has been reported in different populations, but
actually only few studies have focused on HIV population.
Interestingly, in our study we were also able to quantify
the risk of CS-MRSA infection according to the increase of
hospital stay in the previous year, i.e. 14% per an increase
of 5 days (Figure 1).
In our study we also found that attendance to our outpa-
tient clinic was less frequent in MRSA cases than controls.
Possible explanations to this finding include the low inva-
sive procedure rate in the HIV outpatient setting in our
country, resulting in a low exposure rate to nosocomial
organisms; moreover, the higher CD4 cell count we found
among controls may be a protective factor for MRSA colo-
nization according to data reported in literature,[14,23]
and for the occurrence of opportunistic infections that
lead to hospitalization. In consequence, controls are likely
to have more clinical visits in outpatient settings than
cases.
Most of our HC-MRSA infections (63%) had a commu-
nity onset, not far from the 50% rate found by Seybold et
al. among 107 HC-MRSA [14]. Moreover, we found that
about 40% cases had MRSA sepsis and 30% had skin, and
soft tissue infections. Several reports have pointed out on
the higher prevalence of MRSA bloodstream and skin and
soft tissue infections among HIV-infected patients with
respect to other MRSA clinical infections [9,15,16]. The
Table 1: Risk factors for CS-MRSA^ infection in HIV infected patients. Multivariate analysis.
Cases n = 27 Controls n = 54 Univariate analysis Multivariate analysis
Odds Ratio§ 95% CI^^ p* Odds Ratio§ 95% CI^^ p*
HIV risk factor, n (%)
IDU (intravenous drug user) 15 31 1.00 - - - - - - -
Homosexual 2 7 0.50 0.08 3.02 0.449 - - - -
Heterosexual 5 7 1.70 0.41 6.97 0.463 - - - -
Unknown 5 9 1.18 0.33 4.22 0.801 - - - -
Cumulative hospital stay (days) in the previous year
(per an increase of 5 days) - - 1.11 1.02 1.22 0.020 1.14 1.01 1.29 0.041
Outpatient visits in the previous year
0–1 17 19 1.00 - - - 1.00 - - -
more than 1 10 35 0.34 0.13 0.92 0.034 0.26 0.07 1.01 0.051
Any invasive procedure in the previous year**
No 17 51 1.00 - - - 1.00 - - -
Yes 10 3 8.92 1.93 41.31 0.005 9.14 1.31 63.73 0.025
Median CD4 cell count previous half year (cells/μl)
0–199 20 22 1.00 - - - 1.00 - - -
≥ 200 7 32 0.24 0.08 0.73 0.013 0.22 0.05 1.00 0.050
Median Log10HIV plasma viral load (cp/ml) in the previous half year***
≤ 2 . 9 9 9 1 4 1 . 0 0 - -- - - --
≥ 3 17 39 0.69 0.25 1.92 0.478 - - - -
Any ARV therapy in previous 6 months
No 17 41 1.00 - - - - - - -
Yes 10 13 1.86 0.65 5.29 0.245 - - - -
Any cotrimoxazole in the previous 4 months
No 19 49 1.00 - - - - - - -
Yes 8 5 3.06 0.99 9.41 0.051 - - - -
^ CS = clinically significant methicillin-resistant Staphylococcus aureus
^^ 95% confidence intervals
§ All Estimates are adjusted for age at enrolment (< = 42 years and >42 years of age)
* Wald test
** It Includes surgery, dialysis or a permanent indwelling catheter or percutaneous medical device.
*** Only 77 patients considered; 2 patients not added up to total for missing values.BMC Infectious Diseases 2007, 7:36 http://www.biomedcentral.com/1471-2334/7/36
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relatively high rate of MRSA sepsis could in part explain
why our cases had a two-fold mortality rate than controls.
Our study had some limitations, including the limited
number of cases; however, in order to increase the
potency of our study we enrolled two controls per each
case. Furthermore, owing to the retrospective design of
our study, no information is available on previous wide-
spectrum antibiotic treatments, and on other potential
risk factors reported in the literature [12,13]. We may also
have underestimated the total number of hospital days in
the previous year as we did not consider hospitalization in
other hospitals. We believe this information to be of unre-
markable weight because in our country, HIV-infected
inpatients refer only to Infectious Diseases wards for med-
ical acute care, and our Institute is a referral center for
HIV-infected patients in our region. Consequently, it is
likely that almost all cases of CS-MRSA infections occur-
ring in our HIV-infected outpatient population were
admitted to our Institute.
Finally, we are aware that the total number of CS-MRSA
infection diagnosis at our Institute especially in the outpa-
tient settings could have been underestimated because of
the following reasons: 1) our isolates were collected dur-
ing hospital stay whereas in other studies, MRSA isolates
were collected also during outpatient visits [15,16]; 2)
some clinically diagnosed mild infections that do not
require hospitalization could have been treated with
empirical antibiotic therapy, leading to misdiagnosis of
MRSA infection and/or to culture-negative samples when
collected.
Conclusion
In conclusion, our study represents an attempt to evaluate
the potential clinical conditions associated with a CS-
MRSA infection among HIV-infected patient; as recently
proposed by Harbarth et al, these findings could be used
to calculate a risk score at admission [24].
In the clinical management of HIV-infected patients, espe-
cially in those admitted to hospital for clinical sepsis, and/
or skin and soft tissue infections, clinicians should be
aware of the risk factors associated with a MRSA infection,
particularly low CD4 cell count, longer previous hospital
stay and previous invasive procedures.
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